AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) An α-amino acid derivative of the formula (I)

wherein

R¹ is a hydrogen atom, a halogen atom, alkyl or alkoxy,

R² is a hydrogen atom, a halogen atom, a hydroxyl group, alkyl or alkoxy, or

R¹ and R² are joined to form oxo, hydroxyimino, alkoxyimino or alkylidene,

X is $CH-R^3$ or $N-R^4$,

Y is CR⁵R⁶

wherein R⁵ and R⁶ are each a hydrogen atom, a halogen atom, a hydroxyl group, alkyl or alkoxy, or R⁵ and R⁶ are optionally joined to form oxo, hydroxyimino, alkoxyimino or alkylidene,

S, S=O or SO₂,

Z is a hydrogen atom or cyano,

m and n are each 0, 1 or 2, wherein the sum of m and n is 1, 2 or 3,

p is 0, 0 or 1, 2 or 3,

 R^3 is $-NR^7R^8$

wherein R⁷ and R⁸ are optionally the same or different and each independently is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, or are optionally bonded to each other to form heterocycle having at least one nitrogen atom, and optionally having other further hetero atom(s),

wherein the heterocycle is optionally substituted or condensed with an aromatic ring optionally having substituent(s),

-NR⁹COR¹⁰

wherein R⁹ and R¹⁰ are optionally the same or different and each independently is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl or heterocycle,

-NR¹¹CONR¹²R¹³

wherein R¹¹, R¹² and R¹³ are optionally the same or different and each independently is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, or R¹² and R¹³ are optionally bonded to each other to form heterocycle having at least one nitrogen atom, and optionally having other further hetero atom(s),

wherein the heterocycle is optionally substituted or condensed with an aromatic ring optionally having substituent(s),

$-NR^{14}SO_2R^{15}$

wherein R¹⁴ and R¹⁵ are optionally the same or different and each independently is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycle,

-OR16 or -OCOR17

wherein R¹⁶ and R¹⁷ are each a hydrogen atom, alkyl, cycloalkyl, cycloalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycle, and R⁴—is a hydrogen atom, alkyl, cycloalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, COR¹⁸

wherein R^{18} is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl or heterocycle, $-CONR^{19}R^{20}$

wherein R¹⁹ and R²⁰ are optionally the same or different and each independently is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, or R¹⁹ and R²⁰ are optionally bonded to each other to form heterocycle having at least one nitrogen atom, and optionally having other further hetero atom(s),

wherein the heterocycle is optionally substituted or condensed with an aromatic ring optionally having substituent(s), or

 $-SO_2R^{21}$

wherein R²¹ is alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycle,

provided that when p is 0, then X is CH-R³, and R³ shows the is of formula (II)

$$-N A-R^{22} (II)$$

wherein

is a single bond or a double bond,

R²² is aryl or heteroaryl,

Q is 1 or 2, and

A is a carbon atom or a nitrogen atom,

provided that i) when A is a carbon atom, then A is optionally substituted by a hydroxyl group, carboxyl or alkoxycarbonyl, and ii) when A is a nitrogen atom, then

..... is a single bond,

wherein, of the above-mentioned groups, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and heterocycle optionally have substituent(s), or a pharmaceutically acceptable salt thereof.

- 2. (Currently Amended) The α -amino acid derivative of claim 1, wherein m=2, 2 and n=0 and $X=CH-R^3$.
- 3. (Previously Presented) The α -amino acid derivative of claim 1, wherein R^3 is the formula (II).
- 4. (Previously Presented) The α -amino acid derivative of claim 3, wherein $R^1=R^2=Z=H,\,q=1$ and A=N.
 - 5. (Canceled)
 - 6. (Canceled)

7. (Previously Presented) A pharmaceutical composition comprising an α-amino acid derivative of claim 1 or a pharmaceutically acceptable salt thereof and a pharmacologically acceptable carrier.

8.-11. (Canceled)

12. (Currently Amended) A method of producing a compound of claim 1, which comprises a method of producing a compound of formula (III)

wherein

X' is CH- R^3 ,

 R^{23} is $-COR^{24}$

wherein R²⁴ is a hydrogen atom, alkyl, cycloalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycle, or

-COOR²⁵

wherein R^{25} is alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycle,

R¹ is a hydrogen atom, a halogen atom, alkyl or alkoxy,

R² is a hydrogen atom, a halogen atom, a hydroxyl group, alkyl or alkoxy, or

R¹ and R² are joined to form oxo, hydroxyimino, alkoxyimino or alkylidene,

Y is CR⁵R⁶

wherein R⁵ and R⁶ are each a hydrogen atom, a halogen atom, a hydroxyl group, alkyl or alkoxy, or R⁵ and R⁶ are optionally joined to form oxo, hydroxyimino, alkoxyimino or alkylidene,

S, S=O or SO₂₇

Z is a hydrogen atom or cyano,

m and n are each 0, 1 or 2, wherein the sum of m and n is 1, 2 or 3,

p is 0, 0 or 1, 2 or 3,

 R^3 is $-NR^7R^8$

wherein R⁷ and R⁸ are optionally the same or different and each independently is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, or are optionally bonded to each other to form heterocycle having at least one nitrogen atom, and optionally having other further hetero atom(s),

wherein the heterocycle is optionally substituted or condensed with an aromatic ring optionally having substituent(s),

-NR⁹COR¹⁰

wherein R⁹ and R¹⁰ are optionally the same or different and each independently is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl or heterocycle,

-NR¹¹CONR¹²R¹³

wherein R¹¹, R¹² and R¹³ are optionally the same or different and each independently is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, or R¹² and R¹³ are optionally bonded to each other to form heterocycle having at least one nitrogen atom, and optionally having other further hetero atom(s),

wherein the heterocycle is optionally substituted or condensed with an aromatic ring optionally having substituent(s),

$-NR^{14}SO_2R^{15}$

wherein R^{14} and R^{15} are optionally the same or different and each independently is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycle,

-OR¹⁶ or -OCOR¹⁷

wherein R¹⁶ and R¹⁷ are each a hydrogen atom, alkyl, cycloalkyl, cycloalkyl, cycloalkyl, heteroaryl, heteroarylalkyl or heterocycle, and R⁴ is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, COR¹⁸

wherein R¹⁸ is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl or heterocycle,

-CONR¹⁹R²⁰

wherein R¹⁹ and R²⁰ are optionally the same or different and each independently is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, or R¹⁹ and R²⁰ are optionally bonded to each other to form heterocycle having at least one nitrogen atom, and optionally having other further hetero atom(s),

wherein the heterocycle is optionally substituted or condensed with an aromatic ring optionally having substituent(s), or

 $-SO_2R^{21}$

wherein R²¹ is alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycle,

wherein, of the above-mentioned groups, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and heterocycle optionally have substituent(s) comprising use of a compound of formula (III) in which X' is C=O as an intermediate.

13. (Currently Amended) A method of prophylactically or therapeutically treating a GLP-1-related disease type II diabetes or obesity in a subject comprising administering to a subject in need thereof an effective amount of a compound of claim 1 to treat type II diabetes or obesity in the subject.

14.-16. (Canceled)

- 17. (New) A method of therapeutically treating type II diabetes or obesity in a subject comprising administering to a subject in need thereof an effective amount of a compound of claim 2 to treat type II diabetes or obesity in the subject.
- 18. (New) A method of therapeutically treating type II diabetes or obesity in a subject comprising administering to a subject in need thereof an effective amount of a compound of claim 3 to treat type II diabetes or obesity in the subject.
- 19. (New) A method of therapeutically treating type II diabetes or obesity in a subject comprising administering to a subject in need thereof an effective amount of a compound of claim 4 to treat type II diabetes or obesity in the subject.